Chemomab (CMMB): 8.1% ADS Stake Disclosed by Erik Otto

Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class.

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. has a disclosed beneficial owner, Erik Otto, who holds 1,690,000 American Depositary Shares (ADSs), representing 8.1% of the ADS class. Each ADS represents twenty ordinary shares.

Mr. Otto reports sole voting and sole dispositive power over these ADSs and certifies the holdings were not acquired to change or influence control of the issuer. The ownership percentage is stated based on the issuer's count of outstanding ADSs.

Positive

• Clear disclosure of a material stake: 1,690,000 ADSs representing 8.1% of the class
• Sole voting and dispositive power reported, which clarifies control rights over the shares
• Filed on Schedule 13G with a certification of no intent to change control, indicating passive ownership

Negative

• Concentrated ownership (8.1%) could affect liquidity and future governance outcomes
• Filing provides no transaction history or acquisition timing, limiting insight into the holder's investment horizon

Insights

Securities Analyst

TL;DR: A single investor reports an 8.1% passive ADS stake, disclosed under Schedule 13G; this is material but appears non-control.

The filing shows 1,690,000 ADSs (8.1%) held by an individual with sole voting and dispositive power. Because the report is on Schedule 13G and includes a certification that the stake was not acquired to influence control, this is a passive disclosure rather than an active takeover signal. For investors, an >5% holder is material because it concentrates ownership and can affect liquidity and voting outcomes, but absent additional transactions or coordination this filing alone is neutral for corporate control.

Corporate Governance Expert

TL;DR: Ownership concentration is meaningful for governance; the filer states no intent to change control, keeping immediate governance risk low.

The report documents a sizable single-owner position at 8.1% with sole voting power, which makes the holder a significant stakeholder for proxy matters and voting blocs. The certification that the shares were not acquired to influence control and the use of Schedule 13G suggest passive intent, reducing immediate takeover concerns. Nevertheless, an 8.1% holder warrants attention from the board and other investors because future activity by this holder could materially affect shareholder votes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Chemomab (CMMB) ADSs does Erik Otto own?

Erik Otto reports beneficial ownership of 1,690,000 ADSs, representing 8.1% of the ADS class.

Does Erik Otto have voting power over the ADSs?

Yes. The filing states Mr. Otto has sole voting power and sole dispositive power over the 1,690,000 ADSs.

Is this ownership reported as passive or active (Schedule 13G vs 13D)?

The submission is a Schedule 13G amendment and includes a certification that the shares were not acquired to change or influence control, indicating a passive filing.

Is the stake held on behalf of another person or entity?

No. Item 6 is marked Not Applicable, indicating the filing does not report ownership on behalf of another person.

What basis is used to calculate the 8.1% ownership figure?

The percentage is based on the issuer's stated count of outstanding ADSs (the filing cites the issuer-provided outstanding ADS total).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 01:04 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Chemomab Therapeutics Ltd.

(Name of Issuer)

American Depository Shares, each of which represent twenty ordinary shares, no par value

(Title of Class of Securities)

36322Q107

(CUSIP Number)

08/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 36322Q107

1

Names of Reporting Persons

Otto Erik

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BRITISH COLUMBIA, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,690,000.00
6	Shared Voting Power
7	Sole Dispositive Power 1,690,000.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,690,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.1 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Percent of class based on 20,764,302 ADSs outstanding as of July 23, 2025 (As provided by the Issuer)

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: KIRYAT ATIDIM, BUILDING 7, KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ISRAEL, 6158002
Item 2.
(a)	Name of person filing: Erik Otto
(b)	Address or principal business office or, if none, residence: 144 West Oakview Place, San Antonio, Texas, 78209
(c)	Citizenship: Canada
(d)	Title of class of securities: American Depository Shares, each of which represent twenty ordinary shares, no par value
(e)	CUSIP No.: 36322Q107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,690,000
(b)	Percent of class: 8.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,690,000
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of: 1,690,000
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Otto Erik

Signature:	Erik Otto
Name/Title:	Individual
Date:	08/11/2025